Gravity Analytica

Wave Life Sciences Third Quarter 2024 Financial Results Scheduled for November 12, 2024

WVE 11.04.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-12

Name of Upcoming Event:Wave Life Sciences Third Quarter 2024 Financial Results Review

Full Press Release SEC Filings Our WVE Tweets

About Gravity Analytica

Recent Filings

CAMBRIDGE, Mass.,Nov. 04, 2024(GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at8:30 a.m. ETonTuesday, November 12, 2024, to review the company’s third quarter 2024 financial results and provide business updates.

The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of theWave Life Scienceswebsite:https://ir.wavelifesciences.com/events-publications/events.

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link:available here. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on theWave Life Scienceswebsite.

About Wave Life SciencesWave Life Sciences(Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM^®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. Driven by the calling to “Reimagine Possible”, Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered inCambridge, MA.For more information on Wave’s science, pipeline and people, please visitwww.wavelifesciences.comand follow Wave onX(formerly Twitter) andLinkedIn.

Investor Contact:Kate Rausch+1 617-949-4827krausch@wavelifesci.com

Media Contact:Alicia Suter+1 617-949-4817asuter@wavelifesci.com

Source: Wave Life Sciences USA, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com